Equities

Nuwellis Inc

Nuwellis Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.206
  • Today's Change0.073 / 54.89%
  • Shares traded72.29m
  • 1 Year change-95.53%
  • Beta0.3108
Data delayed at least 15 minutes, as of May 02 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nuwellis, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.

  • Revenue in USD (TTM)8.86m
  • Net income in USD-22.63m
  • Incorporated2002
  • Employees59.00
  • Location
    Nuwellis Inc12988 Valley View RdEDEN PRAIRIE 55344-3657United StatesUSA
  • Phone+1 (952) 345-4200
  • Fax+1 (302) 636-5454
  • Websitehttps://www.nuwellis.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bone Biologics Corp0.00-8.95m1.48m2.00--0.3088-----77.05-77.050.005.440.00----0.00-146.30-98.31-202.15--------------0.00-------502.76------
Escalon Medical Corp12.38m450.50k1.48m38.007.721.582.990.11980.02590.02591.180.19512.654.048.01325,898.7014.68-1.7635.71-3.6746.2644.575.54-0.91141.0931.900.1504--13.801.33760.89-17.06-19.85--
Nemaura Medical Inc0.00-10.65m1.54m36.00---------0.3787-0.37870.00-0.61690.000.00--0.00-117.49-58.18---131.96-------7,384.830.0305-1.4710.81---84.71---1.85--64.14--
Tivic Health Systems Inc1.23m-8.26m1.57m16.00--0.2721--1.28-42.45-42.452.753.930.16131.0710.8676,687.50-108.51---135.42--26.49---672.78--5.53--0.00--46.38---18.86------
Grapefruit USA Inc34.85k-4.37m1.66m9.00------47.63-0.008-0.0080.00006-0.01010.01211.310.22593,872.22-151.85-268.93-----1,304.65-10.09-12,531.68-408.870.0388-1.50-----83.9677.87-35.68------
Prosomnus Inc25.61m-15.02m1.74m129.00------0.0679-0.942-0.9421.52-1.331.2011.868.85198,496.50-70.44---164.95--52.38---58.65--1.38-3.152.57--37.79---19.54------
NanoVibronix Inc2.28m-3.71m1.92m10.00--0.354--0.8415-2.15-2.151.301.950.36370.304113.96228,300.00-59.13-116.16-95.36-169.3667.3250.47-162.55-570.471.53-13.970.00--203.5948.3331.88---34.02--
Nuwellis Inc8.86m-22.63m2.02m59.00--0.2528--0.2284-13.45-13.454.510.56510.51471.675.28150,237.30-117.35-98.07-152.04-122.4856.2255.22-227.99-230.511.96-5.060.00--3.7612.14-55.78--4.61--
VirExit Technologies Inc0.00-1.80m2.28m-----------0.0932-0.1130.00-0.03670.00-------6,103.43-----------------3.66-----100.00--19.08------
SINTX Technologies Inc2.63m-8.29m2.39m43.00--0.0283--0.908-2.03-2.030.70411.650.16871.345.1961,093.02-53.05-45.71-81.96-57.3670.1658.47-314.39-681.801.60--0.0052--68.2994.2449.75--54.10--
Dynatronics Corp35.18m-5.70m2.47m154.00--0.3031--0.0701-1.38-1.388.393.431.093.167.84228,421.30-15.46-6.02-21.69-8.3021.5227.33-14.12-4.550.6695-19.740.1955---8.41-8.81-19.84---5.11--
Bioelectronics Corp1.61m-289.82k2.47m9.00------1.53-0.00002-0.000020.00007-0.00066.329.2014.53---113.86-383.59----49.4351.48-18.01-143.480.0099-0.4909----94.01-5.0975.01------
Therapeutic Solutions International Inc98.99k-2.17m2.54m3.00--2.03--25.64-0.0007-0.00070.000030.00030.02871.134.4432,996.67-64.51-162.32-169.11--62.8567.79-2,247.41-2,391.850.0333-4.920.373---52.1395.3543.11------
Innovative Eyewear Inc1.15m-6.66m2.62m11.00--0.4603--2.28-0.6442-0.64420.10980.43030.21134.0511.33104,770.90-122.17---137.62---10.35---578.18--8.14-2,255.110.00--74.67---17.28------
Vycor Medical Inc1.46m-387.45k2.74m8.00------1.88-0.0122-0.01240.0432-0.10191.580.60027.86182,575.00-6.81-47.86----90.0889.60-4.32-35.420.08590.389----19.43-0.654246.49---31.77--
Data as of May 02 2024. Currency figures normalised to Nuwellis Inc's reporting currency: US Dollar USD

Institutional shareholders

3.13%Per cent of shares held by top holders
HolderShares% Held
Renaissance Technologies LLCas of 31 Dec 202354.80k0.81%
Virtu Americas LLCas of 31 Dec 202354.51k0.80%
The Vanguard Group, Inc.as of 31 Dec 202349.96k0.73%
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 202321.69k0.32%
Citadel Securities LLCas of 31 Dec 202319.49k0.29%
Geode Capital Management LLCas of 31 Dec 202311.22k0.17%
Tower Research Capital LLCas of 31 Dec 20231.35k0.02%
JPMorgan Securities LLC (Investment Management)as of 31 Dec 202357.000.00%
Wells Fargo Bank, NA (Private Banking)as of 31 Dec 202325.000.00%
Qube Research & Technologies Ltd.as of 31 Dec 20238.000.00%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.